0
Abstract: Poster Presentations |

THEOPHYLLINE REDUCES SERUM LEVELS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH LUNG DISEASE AND COEXISTENT CARDIAC DISORDERS FREE TO VIEW

Siegfried Wieshammer, MD*; Jens Dreyhaupt, PhD; Beate Basler, RT; Emil Marsovszky, MD
Author and Funding Information

Klinikum Offenburg, Offenburg, Germany


Chest


Chest. 2009;136(4_MeetingAbstracts):103S. doi:10.1378/chest.136.4_MeetingAbstracts.103S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Although downgraded to third line therapy in current guidelines, theophylline is still widely used for treating obstructive airway disease. The appreciation of its anti-inflammatory actions at low serum concentrations has revived interest in this drug but its cardiac side effects are still a concern. N-terminal pro-brain natriuretic peptide (NT-proBNP) provides prognostic information and is increasingly recognized as a quantitative indicator of myocardial stress. This prospective study aimed to determine the effect of theophylline on NT-proBNP in outpatients, who were referred from primary care for pulmonologist evaluation of chronic dyspnea. We hypothesized that theophylline would increase NT-proBNP.

METHODS:  A total of 85 out of 730 patients reported taking theophylline for ≥ 4 weeks and had detectable serum concentrations. All patients underwent a comprehensive diagnostic work-up for both heart and lung disease. The effect of theophylline on NT-proBNP was evaluated by multiple regression analysis after adjustment for the type of heart disease (impaired left ventricular systolic function, atrial fibrillation, pulmonary hypertension, significant valvular disease, exercise-induced myocardial ischemia, or left ventricular hypertrophy) and important non-cardiac covariates (age, sex, BMI, and arterial hypertension).

RESULTS:  The median theophylline serum concentration was 7.8 mg/l [interquartile range 4.6–11.5 mg/l]. After adjustment for the above-mentioned covariates, NT-proBNP was lower in patients on theophylline than in those not taking theophylline in the whole study group (n = 730; p = 0.03) and in those having both heart and lung disease (n = 147, p = 0.02). By contrast, theophylline had no effect on NT-proBNP in patients with lung disease and without heart disease (n = 434, p = 0.68).

CONCLUSION:  Theophylline tends to reduce serum levels of NT-proBNP in patients with lung disease and coexistent cardiac disorders.

CLINICAL IMPLICATIONS:  A low-dose theophylline therapy does not put an excess burden on the heart. The mechanism by which theophylline reduces NT-proBNP levels remains speculative. A theophylline-mediated decrease in ventricular filling pressures may play a role.

DISCLOSURE:  Siegfried Wieshammer, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543